Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma-Reference-Cited by-同舟云学术

Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma

Published:2014-10-28 Issue:10 Volume:111 Page:1909-1916
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Suttle A B,Ball H A,Molimard M,Hutson T E,Carpenter C,Rajagopalan D,Lin Y,Swann S,Amado R,Pandite L

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc2014503.pdf

Reference35 articles.

1. Australian Government Department of Health and Ageing (2010) Drugs designated as orphan drugs: Pazopanib (PATORMA) http://www.tga.gov.au/industry/pm-orphan-drugs.htm .

2. Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, Lehman M, Adams BJ, Bello CL, DePrimo SE, Baum CM, Miller KD (2008) Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 26 (11): 1810–1816.

3. Cacheux W, Boisserie T, Staudacher L, Vignaux O, Dousset B, Soubrane O, Terris B, Mateus C, Chaussade S, Goldwasser F (2008) Reversible tumor growth acceleration following bevacizumab interruption in metastatic colorectal cancer patients scheduled for surgery. Ann Oncol 19 (9): 1659–1661.

4. Deng Y, Sychterz C, Suttle AB, Dar MM, Bershas D, Negash K, Qian Y, Chen EP, Gorycki PD, Ho MY (2013) Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer. Xenobiotica 43 (5): 443–453.

5. Deprimo SE, Bello CL, Smeraglia J, Baum CM, Spinella D, Rini BI, Michaelson MD, Motzer RJ (2007) Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med 5: 32.

Cited by 160 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association of Plasma Cabozantinib Concentration With Treatment Response and Adverse Events in Japanese Patients With Advanced Renal Cell Carcinoma;Therapeutic Drug Monitoring;2024-08-29

2. Exploring the contribution of genetic variants to high sunitinib exposure in patients with cancer;British Journal of Clinical Pharmacology;2024-08-06

3. Evaluating the Clinical Impact and Feasibility of Therapeutic Drug Monitoring of Pazopanib in a Real-World Soft-Tissue Sarcoma Cohort;Clinical Pharmacokinetics;2024-07

4. Therapeutic Drug Monitoring for Tyrosine Kinase Inhibitors in Metastatic Renal Cell Carcinoma;Clinical Genitourinary Cancer;2024-06

5. Concomitant Administration of VEGFR Tyrosine Kinase and Proton Pump Inhibitors May Impair Clinical Outcome of Patients With Metastatic Renal Cancer;Clinical Genitourinary Cancer;2024-06